Twist Bioscience had its Relative Strength (RS) Rating upgraded from 69 to 74 Friday — a welcome improvement, but still shy of the 80 or better score you look for.
IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks compares to the rest of the market.
History shows that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating as they launch their biggest climbs. See if Twist Bioscience can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Twist Bioscience is not currently showing a potential entry point. See if the stock goes on to build a sound pattern that could ignite a new run.
Twist Bioscience showed 0% earnings growth in its most recent report. Sales gains came in at 27%.
Twist Bioscience earns the No. 164 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
